No 1 MANUFACTURER OF MEDICAL EQUIPMENT
IN RUSSIA RECOGNIZED WORLDWIDE

Transcranial pulsed electromagnetic fields as a new possible way to treat patients with clinical depression

Transcranial pulsed electromagnetic fields as a new possible way to treat patients with clinical depression
21.07.2017

Clinical or major depression is a complex psychological disorder that affects mental, emotional and physical state of an individual. MDD (major depressive disorder) is occurring more and more often within different social and demographic groups in the western part of the world according to various contemporary studies.

Due to its complex nature there are many different approaches to the illness treatment, the most common being oral drugs. However, approximately 30% of patients with depression are resistant to antidepressant drugs.

Here are the results of a study during which repetitive transcranial magnetic stimulation (rTMS) was performed on a group of patients suffering from major depression. RTMS has been found effective in combination with antidepressants in this patient group.

The aim of this study was to evaluate the antidepressant effect of a new principle using low-intensity transcranially applied pulsed electromagnetic fields (T-PEMF) in combination with antidepressants in patients with treatment-resistant depression.

This was a sham-controlled double-blind study comparing 5 weeks of active or sham T-PEMF in patients with treatment-resistant major depression. The antidepressant treatment, to which patients had been resistant, was unchanged 4 weeks before and during the study period. Weekly assessments were performed using both clinician-rated and patient-rated scales.

The T-PEMF equipment was designed as a helmet containing seven separate coils located over the skull that generated an electrical field in tissue with orders of magnitude weaker than those generated by rTMS equipment.

Patients on active T-PEMF showed a clinically and statistically significant better outcome than patients treated with sham T-PEMF, with an onset of action within the first weeks of therapy. Effect size on the Hamilton 17-item Depression Rating Scale was .62 (95% confidence interval .21-1.02). Treatment-emergent side effects were few and mild.

The T-PEMF treatment was superior to sham treatment in patients with treatment-resistant depression. Mechanism of the antidepressant action, in light of the known effects of PEMF stimulation to the brain, is discussed.

One of the well-known PEMF devices appropriate for positive impact on the central nervous system is Diamag®.  It is designed for physiotherapy of brain diseases with a low-frequency low-intensity magnetic field.

Diamag® triggers melatonin production and normalizes blood pressure, which reduces the level of anxiety and generally stabilizes nervous system. Diamag relieves headaches, stabilizes brain functioning. Learn more about Diamag® here.

Source: Pub.Med.gov

© Yelatma Instrument Making Enterprise, JSC, 2009—2019
The production is certified: EN ISO 13485:2016, MDD 93/42/EEC (TUV NORD CERT GmbH, Germany)
BIN 1026200861620 from 20.11.02 serial 62 N 000337033